About
Biosimilars
Areas of Focus
Categories
BiosimilarsBiologics & BiopharmaceuticalNJ, NY, PA
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
1,004
By Phase
PHASE3: 5
By Status
COMPLETED: 4ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06190093Lead Sponsor
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)
PHASE3Completed
400 participants
Started: Jan 24, 2024 · Completed: Dec 5, 2024
NCT05112861Lead Sponsor
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
PHASE3Active, not recruiting
120 participants
Started: Nov 15, 2021 · Completed: Mar 31, 2025
NCT04516278Lead Sponsor
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
PHASE3Completed
195 participants
Started: Oct 1, 2020 · Completed: Feb 10, 2021
NCT03834753Lead Sponsor
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
PHASE3Completed
228 participants
Started: Jun 25, 2019 · Completed: Jul 8, 2021
NCT03844074Lead Sponsor
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
PHASE3Completed
61 participants
Started: Oct 1, 2018 · Completed: Aug 13, 2020
Locations (1)
Headquarters
Iselin, NJ, United States
Map
Loading map...